The effect of myo-inositol supplementation on NAFLD

Phase 3

• Conditions: non-alcoholic fatty liver.; Fatty (change of) liver, not elsewhere classified; K76.0

• Registration Number: IRCT20100209003320N22
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Age 18-55 years
Body mass index in the range of 30-40 Kg / m2
Willingness to cooperate
Hepatic steatosis based on Grade 1 and 2 NAFLD disease

Exclusion Criteria

Athlete, pregnancy, lactation and menopause in women
Infertility treatment, taking oral contraceptive pills
Smoking and alcohol use
Adherence to a special diet 3 months before the study
Use of chemical or herbal medicines for weight loss and use of hepatotoxic drugs such as phenytoin, amoxifine , lithium and antihypertensive drugs and lipid-lowering drugs (statins), insulin sensitiser medications
Taking antibiotics or dietary supplements that affect the levels of liver enzymes
History of weight loss surgery over the last year or rigid weight loss diets three months before the trial
Use of corticosteroids and NSAIDs or any type of supplements for 3 months before or during the study
Use of any multivitamin (vitamin E and folic acid, etc.), antioxidants (L-arginine, glutamine) and fish oil supplements for 3 months before or during the study
those with cardiovascular disease, hepatic, renal, intestinal, thyroid and parathyroid dysfunction, billiary disease, known autoimmune diseases, PCOs, cancers and conditions with mal-absorption such as Sprue and Crohn
Having symptoms of a recent infectious, inflammatory disease or recent surgery
Candidate or history of Liver transplant
Intention for pregnancy

Study & Design

• Study Type: interventional
• Study Design: Not specified